SOLITENS: Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome
Study Details
Study Description
Brief Summary
-
To determine if the T-PTNS is not inferior in the short term (3 months) to one of the usual pharmacological treatments (Solifenacin) in the treatment of hyperactive bladder syndrome and with respect to the percentage of patients that improve 50% any of the 3 signs (Urinary frequency, diurnal / nocturnal frequency, urgency and urinary incontinence).
-
To determine prognostic factors associated with insufficient improvement (less than 50% in the 3 main signs of hyperactive bladder syndrome (urinary frequency, urgency and urinary incontinence frequency) after treatment with T-PTNS and Solifenacin.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 4 |
Detailed Description
Patients will be randomized to receive the usual standard treatment with Solifenacin or treatment based on peripheral unilateral transcutaneous neuromodulation of the posterior tibial nerve .
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Medical device: Transcutaneous electrical neurostimulation Medical device 4 weeks with daily sessions of 30 minutes |
Device: Neuro-Muscular Stimulators (NMS)
Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
Other Names:
|
| Active Comparator: Solifenacin 10 mg tablet daily during 75 days maximum |
Drug: Solifenacin Succinate
10 mg tablet daily during 75 days maximum
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Evaluate whether treatment with T-PTNS is not less than 3 months compared to the current standard pharmacological treatments regarding the episodes of urgency, urinary frequency, incontinence and nocturia, all measured with the 3-day voiding diary [12 weeks]
3- day voiding diary
Eligibility Criteria
Criteria
Inclusion Criteria:
- Women> 18 years, diagnosed with hyperactive bladder syndrome for at least 6 months of evolution and who have taken Beta 3 agonists
Exclusion Criteria:
-
Patients who can contribute biased information: have previously consumed and abandoned anticholinergic drugs due to lack of efficacy or side effects; Suffering from hyperactive bladder of neurogenic origin (multiple sclerosis, Parkinson's, spinal cord injury); Present cystocele or any pelvic organ prolapse> 2 according to Pelvic Organ Prolapse-Q classification
-
Patients who may become worse with the interventions envisaged in the study: being a implantable automatic defibrillators; With cutaneous alterations in lower extremities that prevent the placement of electrodes on the surface; Women who are pregnant or who may be pregnant during the duration of the clinical trial (prior and at each evaluation visit urine Bhcg will be requested to rule out pregnancy) or patients who are not able to manage transcutaneous electrical neurostimulation on an outpatient basis ) Or patients in whom Solifenacin is contraindicated: urinary retention, severe gastrointestinal disorders (including toxic megacolon), myasthenia gravis, or narrow-angle glaucoma, and in patients at risk of these conditions as hypersensitive at first Active or to any of the excipients, undergoing hemodialysis, with moderate hepatic insufficiency or severe renal insufficiency or in simultaneous treatment with a potent inhibitor of CYP3A4, eg ketoconazole.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Hospital Clínico Universtario Virgen de la Arrixaca | El Palmar | Murcia | Spain | 30120 |
Sponsors and Collaborators
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Investigators
- Principal Investigator: José David Jiménez Parra, MD, Hospital Rafael Méndez (Lorca, Murcia. SPAIN)
- Principal Investigator: María Luisa María Luisa, MD, Hospital Clínica Universitario Virgen de la Arrixaca (SPAIN)
- Principal Investigator: José Felix Escudero Bregante, MD, Hospital Clínico Universitario Virgen de la Arrixaca (SPAIN)
- Principal Investigator: Julián Oñate, MD, Hospital General Universitario Reina Sofía (SPAIN)
- Principal Investigator: Ana Isabel López López, MD, Hospital Clínico Universitario San Juan (SPAIN)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FFIS/2017/01/SLT
- 2017-000605-20